{"disease":{"id":"migraine","name":"Migraine","therapeutic_area":"Neurology","data":{"aiSummary":"The treatment landscape for migraine has evolved significantly, with the introduction of CGRP inhibitors (erenumab, galcanezumab, fremanezumab, eptinezumab) and gepants (ubrogepant, rimegepant) offering new options for both acute and preventive treatment. These therapies have shown efficacy in reducing migraine frequency and severity. The pipeline includes further development of gepants and CGRP antibodies, as well as other novel mechanisms of action. The focus is on personalized medicine approaches, considering individual patient characteristics and response to treatment.","drug_count":8,"description":"Migraine is a common neurological disorder characterized by recurrent episodes of moderate to severe headache, often accompanied by nausea, vomiting, and sensitivity to light, sound, and smell. The pathophysiology involves complex interactions between the trigeminovascular system, cortical spreading depression, and genetic factors. Current treatments focus on abortive therapies to stop attacks and preventive therapies to reduce attack frequency and severity.","subtype_count":10},"enrichment_level":2,"last_enriched_at":null,"visit_count":0,"created_at":"2026-03-25T12:16:34.944Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":28,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"onabotulinumtoxina","indication_name":"Chronic Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Botox","generic_name":"ONABOTULINUMTOXINA","company_name":"Allergan","drug_phase":"marketed","molecular_target":"SNAP-25","drug_class":"Acetylcholine Release Inhibitor [EPC]","quality_score":60,"revenue":"5300","mechanism":"BOTOX blocks neuromuscular transmission by inhibiting acetylcholine release through cleavage of SNAP-25."},{"drug_id":"nurtec-odt","indication_name":"Prevention of migraine attacks","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nurtec Odt","generic_name":"Rimegepant Sulfate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Calcitonin gene-related peptide (CGRP) receptor","drug_class":"CGRP receptor antagonist","quality_score":85,"revenue":"1424","mechanism":"Rimegepant is a calcitonin gene-related peptide receptor antagonist."},{"drug_id":"nurtec-odt","indication_name":"Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nurtec Odt","generic_name":"Rimegepant Sulfate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Calcitonin gene-related peptide (CGRP) receptor","drug_class":"CGRP receptor antagonist","quality_score":85,"revenue":"1424","mechanism":"Rimegepant is a calcitonin gene-related peptide receptor antagonist."},{"drug_id":"rimegepant-75mg-every-other-day-dosing","indication_name":"Prevention of migraine attacks in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rimegepant 75mg every other day dosing","generic_name":"rimegepant-75mg-every-other-day-dosing","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"calcitonin gene-related peptide receptor","drug_class":"calcitonin gene-related peptide receptor antagonist","quality_score":64,"revenue":"798","mechanism":"Rimegepant targets the calcitonin gene-related peptide receptor to treat migraines."},{"drug_id":"rimegepant-75mg-every-other-day-dosing","indication_name":"Acute treatment of migraine attacks with or without aura in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rimegepant 75mg every other day dosing","generic_name":"rimegepant-75mg-every-other-day-dosing","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"calcitonin gene-related peptide receptor","drug_class":"calcitonin gene-related peptide receptor antagonist","quality_score":64,"revenue":"798","mechanism":"Rimegepant targets the calcitonin gene-related peptide receptor to treat migraines."},{"drug_id":"ubrogepant","indication_name":"Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ubrelvy","generic_name":"UBROGEPANT","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Calcitonin gene-related peptide type 1 receptor","drug_class":"Calcitonin Gene-related Peptide Receptor Antagonist [EPC]","quality_score":65,"revenue":"664","mechanism":"Ubrelvy blocks the action of a molecule called calcitonin gene-related peptide, which is involved in migraine pain."},{"drug_id":"fremanezumab","indication_name":"Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ajovy","generic_name":"FREMANEZUMAB","company_name":"Teva","drug_phase":"marketed","molecular_target":"Calcitonin gene-related peptide 1","drug_class":"","quality_score":66,"revenue":"600","mechanism":"Ajovy works by blocking the action of calcitonin gene-related peptide 1 (CGRP1), a molecule involved in pain transmission."},{"drug_id":"fremanezumab","indication_name":"Prevention of migraine attacks","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ajovy","generic_name":"FREMANEZUMAB","company_name":"Teva","drug_phase":"marketed","molecular_target":"Calcitonin gene-related peptide 1","drug_class":"","quality_score":66,"revenue":"600","mechanism":"Ajovy works by blocking the action of calcitonin gene-related peptide 1 (CGRP1), a molecule involved in pain transmission."},{"drug_id":"erenumab","indication_name":"Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aimovig","generic_name":"ERENUMAB","company_name":"Amgen","drug_phase":"marketed","molecular_target":"Calcitonin-gene-related peptide receptor","drug_class":"","quality_score":70,"revenue":"500","mechanism":"Aimovig works by blocking the calcitonin-gene-related peptide receptor, a protein involved in migraine pain."},{"drug_id":"galcanezumab","indication_name":"Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Emgality","generic_name":"GALCANEZUMAB","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Calcitonin gene-related peptide 1","drug_class":"","quality_score":60,"revenue":"500","mechanism":"Emgality works by binding to calcitonin gene-related peptide 1 (CGRP1), preventing it from triggering migraine attacks."},{"drug_id":"erenumab","indication_name":"Prevention of migraine attacks","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aimovig","generic_name":"ERENUMAB","company_name":"Amgen","drug_phase":"marketed","molecular_target":"Calcitonin-gene-related peptide receptor","drug_class":"","quality_score":70,"revenue":"500","mechanism":"Aimovig works by blocking the calcitonin-gene-related peptide receptor, a protein involved in migraine pain."},{"drug_id":"galcanezumab","indication_name":"Preventive treatment of migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Emgality","generic_name":"GALCANEZUMAB","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Calcitonin gene-related peptide 1","drug_class":"","quality_score":60,"revenue":"500","mechanism":"Emgality works by binding to calcitonin gene-related peptide 1 (CGRP1), preventing it from triggering migraine attacks."},{"drug_id":"eptinezumab","indication_name":"Prevention of migraine attacks","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyepti","generic_name":"EPTINEZUMAB","company_name":"Lundbeck Seattle BioPharmaceuticals, Inc.","drug_phase":"marketed","molecular_target":"Calcitonin gene-related peptide 1","drug_class":"Calcitonin Gene-related Peptide Antagonist [EPC]","quality_score":66,"revenue":"300","mechanism":"Vyepti works by blocking the action of calcitonin gene-related peptide 1, a molecule involved in migraine pain."},{"drug_id":"eptinezumab","indication_name":"Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyepti","generic_name":"EPTINEZUMAB","company_name":"Lundbeck Seattle BioPharmaceuticals, Inc.","drug_phase":"marketed","molecular_target":"Calcitonin gene-related peptide 1","drug_class":"Calcitonin Gene-related Peptide Antagonist [EPC]","quality_score":66,"revenue":"300","mechanism":"Vyepti works by blocking the action of calcitonin gene-related peptide 1, a molecule involved in migraine pain."},{"drug_id":"atogepant","indication_name":"Preventive treatment of migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Qulipta","generic_name":"ATOGEPANT","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Calcitonin gene-related peptide type 1 receptor","drug_class":"Calcitonin Gene-related Peptide Receptor Antagonist [EPC]","quality_score":66,"revenue":"201","mechanism":"Qulipta works by blocking the action of a natural chemical called calcitonin gene-related peptide type 1, which is involved in migraine pain."},{"drug_id":"atogepant","indication_name":"Preventive treatment of episodic migraine in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Qulipta","generic_name":"ATOGEPANT","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Calcitonin gene-related peptide type 1 receptor","drug_class":"Calcitonin Gene-related Peptide Receptor Antagonist [EPC]","quality_score":66,"revenue":"201","mechanism":"Qulipta works by blocking the action of a natural chemical called calcitonin gene-related peptide type 1, which is involved in migraine pain."},{"drug_id":"caffeine","indication_name":"Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Norgesic","generic_name":"caffeine","company_name":"Hikma","drug_phase":"marketed","molecular_target":"Adenosine receptor A2a","drug_class":"Central Nervous System Stimulant [EPC]","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"bhv-3500-zavegepant","indication_name":"Acute migraine treatment","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BHV-3500 (zavegepant)","generic_name":"bhv-3500-zavegepant","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"CGRP receptor (calcitonin gene-related peptide receptor)","drug_class":"CGRP receptor antagonist","quality_score":30,"revenue":null,"mechanism":"Zavegepant is a CGRP receptor antagonist that blocks neuropeptide signaling to reduce migraine pain and associated symptoms."},{"drug_id":"bhv-3500-zavegepant","indication_name":"Acute migraine treatment","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BHV-3500 (zavegepant)","generic_name":"bhv-3500-zavegepant","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"CGRP receptor (calcitonin gene-related peptide receptor)","drug_class":"CGRP receptor antagonist","quality_score":30,"revenue":null,"mechanism":"Zavegepant is a CGRP receptor antagonist that blocks neuropeptide signaling to reduce migraine pain and associated symptoms."},{"drug_id":"oxetorone","indication_name":"Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"OXETORONE","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"oxetorone","quality_score":null,"revenue":null,"mechanism":"Oxetorone is thought to work by modulating the activity of certain neurotransmitters involved in pain transmission."},{"drug_id":"bat","indication_name":"Treatment of migraine in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"rimegepant-for-acute-migraine-treatment","indication_name":"Acute treatment of migraine with or without aura in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rimegepant for acute migraine treatment","generic_name":"rimegepant-for-acute-migraine-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"calcitonin gene-related peptide receptor","drug_class":"calcitonin gene-related peptide receptor antagonist","quality_score":54,"revenue":null,"mechanism":"Rimegepant targets the calcitonin gene-related peptide receptor to treat acute migraine."},{"drug_id":"ergot","indication_name":"Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ergot","company_name":"Samuel Lunenfeld Research Institute, Mount Sinai Hospital","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"rimegepant-75mg-orally-disintegrating-tablets-odt","indication_name":"Acute treatment of migraine attacks with or without aura in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rimegepant 75mg Orally Disintegrating Tablets (ODT)","generic_name":"rimegepant-75mg-orally-disintegrating-tablets-odt","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"calcitonin gene-related peptide receptor","drug_class":"calcitonin gene-related peptide receptor antagonist","quality_score":51,"revenue":null,"mechanism":"Rimegepant is a calcitonin gene-related peptide receptor antagonist."},{"drug_id":"eptinezumab-jjmr","indication_name":"Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"VYEPTI","generic_name":"EPTINEZUMAB-JJMR","company_name":"Lundbeck Seattle BioPharmaceuticals, Inc.","drug_phase":"marketed","molecular_target":"Calcitonin gene-related peptide 1, Calcitonin gene-related peptide 2","drug_class":"Calcitonin Gene-related Peptide Antagonist [EPC]","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"eptinezumab-jjmr","indication_name":"Prevention of migraine attacks","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"VYEPTI","generic_name":"EPTINEZUMAB-JJMR","company_name":"Lundbeck Seattle BioPharmaceuticals, Inc.","drug_phase":"marketed","molecular_target":"Calcitonin gene-related peptide 1, Calcitonin gene-related peptide 2","drug_class":"Calcitonin Gene-related Peptide Antagonist [EPC]","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"rimegepant-75mg-daily-dosing","indication_name":"Acute treatment of migraine attacks with or without aura in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rimegepant 75mg daily dosing","generic_name":"rimegepant-75mg-daily-dosing","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"calcitonin gene-related peptide receptor","drug_class":"calcitonin gene-related peptide receptor antagonist","quality_score":53,"revenue":null,"mechanism":"Rimegepant is a calcitonin gene-related peptide receptor antagonist that inhibits the release of pro-inflammatory peptides."},{"drug_id":"rimegepant-75mg-daily-dosing","indication_name":"Prevention of migraine attacks in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rimegepant 75mg daily dosing","generic_name":"rimegepant-75mg-daily-dosing","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"calcitonin gene-related peptide receptor","drug_class":"calcitonin gene-related peptide receptor antagonist","quality_score":53,"revenue":null,"mechanism":"Rimegepant is a calcitonin gene-related peptide receptor antagonist that inhibits the release of pro-inflammatory peptides."},{"drug_id":"lisuride","indication_name":"Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lisurid","generic_name":"LISURIDE","company_name":"","drug_phase":"phase_3","molecular_target":"Alpha-2A adrenergic receptor","drug_class":"lisuride","quality_score":null,"revenue":null,"mechanism":"Lisuride works by binding to and activating the alpha-2A adrenergic receptor, which helps to regulate various physiological processes."},{"drug_id":"valproic-acid","indication_name":"Migraine Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Depakene","generic_name":"valproic acid","company_name":"Generic (originally Abbott/AbbVie)","drug_phase":"marketed","molecular_target":"Alcohol dehydrogenase [NADP(+)], Histone deacetylase 1, Histone deacetylase 2","drug_class":"Anti-epileptic Agent [EPC]","quality_score":55,"revenue":null,"mechanism":"Broad-spectrum anticonvulsant that enhances GABA activity, blocks sodium and calcium channels, and inhibits histone deacetylase."},{"drug_id":"lasmiditan","indication_name":"Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Reyvow","generic_name":"LASMIDITAN","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1F","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Reyvow works by binding to the 5-HT1F receptor, blocking pain signals in the brain."},{"drug_id":"phenobarbitone","indication_name":"Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"phenobarbitone","company_name":"Institute of Child Health","drug_phase":"phase_1","molecular_target":"Nuclear receptor subfamily 1 group I member 2, Nuclear receptor subfamily 1 group I member 3, GABA-A receptor alpha-1/beta-2/gamma-2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"acetylsalicylic-acid","indication_name":"Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Norgesic","generic_name":"acetylsalicylic acid","company_name":"Endo","drug_phase":"marketed","molecular_target":"reticular formation (brain stem)","drug_class":"centrally acting muscle relaxant with anticholinergic properties","quality_score":82,"revenue":null,"mechanism":"Orphenadrine citrate centrally acts on brain stem to selectively block facilitatory reticular functions."},{"drug_id":"propranolol","indication_name":"Migraine Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inderal","generic_name":"propranolol","company_name":"Generic (originally ICI/AstraZeneca)","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 2 group E member 1, 5-hydroxytryptamine receptor 6, Cytochrome P450 1A2","drug_class":"Non-selective beta-blocker","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"rimegepant-bhv3000","indication_name":"Acute treatment of migraine with or without aura in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rimegepant/BHV3000","generic_name":"rimegepant-bhv3000","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"calcitonin gene-related peptide receptor (CGRPR)","drug_class":"pharmacological class not specified","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"rimegepant-bhv3000","indication_name":"Prevention of migraine in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rimegepant/BHV3000","generic_name":"rimegepant-bhv3000","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"calcitonin gene-related peptide receptor (CGRPR)","drug_class":"pharmacological class not specified","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"almotriptan","indication_name":"Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Axert","generic_name":"ALMOTRIPTAN","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1B","drug_class":"Serotonin-1b and Serotonin-1d Receptor Agonist","quality_score":75,"revenue":null,"mechanism":"Axert works by binding to serotonin receptors in the brain to relieve migraine pain."},{"drug_id":"rimegepant-25-mg","indication_name":"Acute treatment of migraine with or without aura in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rimegepant 25 MG","generic_name":"rimegepant-25-mg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"calcitonin gene-related peptide receptor","drug_class":"calcitonin gene-related peptide receptor antagonist","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"rimegepant-25-mg","indication_name":"Prevention of migraine in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rimegepant 25 MG","generic_name":"rimegepant-25-mg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"calcitonin gene-related peptide receptor","drug_class":"calcitonin gene-related peptide receptor antagonist","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Migraine Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine with Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine with Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine without Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine without Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache with Aura and Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache with Aura and Migraine Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua with Aura and Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua with Aura and Migraine Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine with Aura and Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine with Aura and Migraine Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache without Aura and Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache without Aura and Migraine Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua without Aura and Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua without Aura and Migraine Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine without Aura and Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine without Aura and Migraine Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache with Aura and Migraine with Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache with Aura and Migraine with Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua with Aura and Migraine with Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua with Aura and Migraine with Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine with Aura and Migraine with Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine with Aura and Migraine with Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache without Aura and Migraine with Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache without Aura and Migraine with Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua without Aura and Migraine with Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua without Aura and Migraine with Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine without Aura and Migraine with Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine without Aura and Migraine with Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache with Aura and Migraine without Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache with Aura and Migraine without Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua with Aura and Migraine without Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua with Aura and Migraine without Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine with Aura and Migraine without Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine with Aura and Migraine without Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache without Aura and Migraine without Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache without Aura and Migraine without Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua without Aura and Migraine without Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua without Aura and Migraine without Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine without Aura and Migraine without Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine without Aura and Migraine without Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache with Aura and Migraine with Aura and Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache with Aura and Migraine with Aura and Migraine Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua with Aura and Migraine with Aura and Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua with Aura and Migraine with Aura and Migraine Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine with Aura and Migraine with Aura and Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine with Aura and Migraine with Aura and Migraine Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache without Aura and Migraine with Aura and Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache without Aura and Migraine with Aura and Migraine Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua without Aura and Migraine with Aura and Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua without Aura and Migraine with Aura and Migraine Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine without Aura and Migraine with Aura and Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine without Aura and Migraine with Aura and Migraine Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache with Aura and Migraine without Aura and Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache with Aura and Migraine without Aura and Migraine Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua with Aura and Migraine without Aura and Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua with Aura and Migraine without Aura and Migraine Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine with Aura and Migraine without Aura and Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine with Aura and Migraine without Aura and Migraine Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache without Aura and Migraine with Aura and Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache without Aura and Migraine with Aura and Migraine Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua without Aura and Migraine with Aura and Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua without Aura and Migraine with Aura and Migraine Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine without Aura and Migraine with Aura and Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine without Aura and Migraine with Aura and Migraine Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache with Aura and Migraine without Aura and Migraine without Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache with Aura and Migraine without Aura and Migraine without Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua with Aura and Migraine without Aura and Migraine without Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua with Aura and Migraine without Aura and Migraine without Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine with Aura and Migraine without Aura and Migraine without Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine with Aura and Migraine without Aura and Migraine without Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache without Aura and Migraine with Aura and Migraine without Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache without Aura and Migraine with Aura and Migraine without Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua without Aura and Migraine with Aura and Migraine without Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine without Aura and Migraine with Aura and Migraine without Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine without Aura and Migraine with Aura and Migraine without Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache with Aura and Migraine without Aura and Migraine with Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache with Aura and Migraine without Aura and Migraine with Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua with Aura and Migraine without Aura and Migraine with Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua with Aura and Migraine without Aura and Migraine with Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine with Aura and Migraine without Aura and Migraine with Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine with Aura and Migraine without Aura and Migraine with Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache without Aura and Migraine with Aura and Migraine without Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache without Aura and Migraine with Aura and Migraine without Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua without Aura and Migraine with Aura and Migraine without Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua without Aura and Migraine with Aura and Migraine without Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine without Aura and Migraine with Aura and Migraine without Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Migraine without Aura and Migraine with Aura and Migraine without Aura Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Cluster Headache with Aura and Migraine without Aura and Migraine with Aura and Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"dihydroergotamine","indication_name":"Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Migranal","generic_name":"DIHYDROERGOTAMINE","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"D(3) dopamine receptor","drug_class":"Ergotamine Derivative","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"zolmitriptan","indication_name":"Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zomig","generic_name":"ZOLMITRIPTAN","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1D","drug_class":"Serotonin-1b and Serotonin-1d Receptor Agonist [EPC]","quality_score":75,"revenue":null,"mechanism":"Zolmitriptan works by binding to serotonin receptors in the brain to constrict blood vessels and block pain pathways."},{"drug_id":"paracetamol","indication_name":"Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Acetaminophen","generic_name":"Paracetamol","company_name":"Polymedica","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily V member 4","drug_class":"acetaminophen","quality_score":60,"revenue":null,"mechanism":"Acetaminophen works by blocking pain signals in the brain."},{"drug_id":"zavzpret","indication_name":"Migraine with aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zavzpret","generic_name":"Zavegepant Hydrochloride","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Calcitonin gene-related peptide type 1 receptor","drug_class":"Calcitonin Gene-related Peptide Receptor Antagonist","quality_score":70,"revenue":null,"mechanism":"Zavzpret blocks the action of calcitonin gene-related peptide, a molecule involved in pain transmission."},{"drug_id":"zavzpret","indication_name":"Migraine without aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zavzpret","generic_name":"Zavegepant Hydrochloride","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Calcitonin gene-related peptide type 1 receptor","drug_class":"Calcitonin Gene-related Peptide Receptor Antagonist","quality_score":70,"revenue":null,"mechanism":"Zavzpret blocks the action of calcitonin gene-related peptide, a molecule involved in pain transmission."},{"drug_id":"rimegepant","indication_name":"Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nurtec Odt","generic_name":"rimegepant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"calcitonin gene-related peptide receptor","drug_class":"Calcitonin Gene-related Peptide Receptor Antagonist","quality_score":70,"revenue":null,"mechanism":"Rimegepant blocks the calcitonin gene-related peptide receptor."},{"drug_id":"rimegepant","indication_name":"Prevention of migraine attacks","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nurtec Odt","generic_name":"rimegepant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"calcitonin gene-related peptide receptor","drug_class":"Calcitonin Gene-related Peptide Receptor Antagonist","quality_score":70,"revenue":null,"mechanism":"Rimegepant blocks the calcitonin gene-related peptide receptor."},{"drug_id":"eletriptan","indication_name":"Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Relpax","generic_name":"ELETRIPTAN","company_name":"Upjohn","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1D","drug_class":"Serotonin-1b and Serotonin-1d Receptor Agonist","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"triptans","indication_name":"Acute treatment of migraine attacks with or without aura in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Triptans","generic_name":"triptans","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Serotonin 5-HT1B/1D receptors","drug_class":"Selective serotonin receptor agonists","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"rimegepant-75-mg-odt","indication_name":"Acute treatment of migraine with or without aura in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"rimegepant 75 mg ODT","generic_name":"rimegepant-75-mg-odt","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CGRP receptors","drug_class":"CGRP receptor antagonist","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"rimegepant-75-mg-odt","indication_name":"Prevention of migraine in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"rimegepant 75 mg ODT","generic_name":"rimegepant-75-mg-odt","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CGRP receptors","drug_class":"CGRP receptor antagonist","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"sumatriptan","indication_name":"Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imitrex","generic_name":"SUMATRIPTAN","company_name":"GSK","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1D","drug_class":"Serotonin-1b and Serotonin-1d Receptor Agonist","quality_score":80,"revenue":null,"mechanism":"Imitrex works by binding to serotonin receptors in the brain, specifically the 5-HT1D subtype, to constrict blood vessels and block pain pathways."},{"drug_id":"ergotamine","indication_name":"Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Migergot","generic_name":"ERGOTAMINE","company_name":"","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1A","drug_class":"Central Nervous System Stimulant [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"naratriptan","indication_name":"Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Amerge","generic_name":"NARATRIPTAN","company_name":"GSK","drug_phase":"marketed","molecular_target":"5-HT 1B/1D receptors","drug_class":"Serotonin-1b and Serotonin-1d Receptor Agonist","quality_score":75,"revenue":null,"mechanism":"Naratriptan treats migraines by binding to 5-HT 1B/1D receptors, causing cranial vessel constriction and inhibiting neuropeptide release."},{"drug_id":"vioxx","indication_name":"Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Vioxx","company_name":"M.D. Anderson Cancer Center","drug_phase":"discontinued","molecular_target":"Cytochrome c oxidase subunit 2, Prostaglandin E2 receptor EP2 subtype, Prostaglandin G/H synthase 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"topamax","indication_name":"Migraine Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Topamax","company_name":"Ataturk University","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 1 group I member 2, Carbonic anhydrase 1, Carbonic anhydrase 12","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"divalproex","indication_name":"Migraine Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Divalproex","company_name":"University of Chicago","drug_phase":"marketed","molecular_target":"Alcohol dehydrogenase [NADP(+)], Histone deacetylase 1, Histone deacetylase 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"naproxen","indication_name":"Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aleve","generic_name":"naproxen","company_name":"Generic (originally Syntex)","drug_phase":"marketed","molecular_target":"Aldo-keto reductase family 1 member C2, Aldo-keto reductase family 1 member C3, Prostaglandin G/H synthase 1","drug_class":"NSAID","quality_score":null,"revenue":null,"mechanism":"Reversibly inhibits COX-1 and COX-2 with a long half-life, providing sustained anti-inflammatory, analgesic, and antipyretic effects."},{"drug_id":"pf-07976016-formulation-a","indication_name":"Chronic Hemicrania Continua without Aura and Migraine with Aura and Migraine without Aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"zolmitriptan","indication_name":"Acute treatment of migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zomig","generic_name":"ZOLMITRIPTAN","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1D","drug_class":"Serotonin-1b and Serotonin-1d Receptor Agonist [EPC]","quality_score":75,"revenue":null,"mechanism":"Zolmitriptan works by binding to serotonin receptors in the brain to constrict blood vessels and block pain pathways."},{"drug_id":"eletriptan-hydrobromide","indication_name":"Acute treatment of migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ELETRIPTAN HYDROBROMIDE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"eletriptan","indication_name":"Acute treatment of migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Relpax","generic_name":"ELETRIPTAN","company_name":"Upjohn","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1D","drug_class":"Serotonin-1b and Serotonin-1d Receptor Agonist","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"sodium-sulfate","indication_name":"Migraine headache pain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SODIUM SULFATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"fremanezumab-vfrm","indication_name":"Preventive treatment of migraine in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fremanezumab-Vfrm","company_name":"Manhattan Beach Orthodontics","drug_phase":"marketed","molecular_target":"calcitonin gene-related peptide (CGRP)","drug_class":"","quality_score":40,"revenue":null,"mechanism":"Fremanezumab-vfrm binds to CGRP and blocks its interaction with the receptor."},{"drug_id":"fremanezumab-vfrm","indication_name":"Preventive treatment of episodic migraine in pediatric patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fremanezumab-Vfrm","company_name":"Manhattan Beach Orthodontics","drug_phase":"marketed","molecular_target":"calcitonin gene-related peptide (CGRP)","drug_class":"","quality_score":40,"revenue":null,"mechanism":"Fremanezumab-vfrm binds to CGRP and blocks its interaction with the receptor."},{"drug_id":"naratriptan","indication_name":"Acute treatment of migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Amerge","generic_name":"NARATRIPTAN","company_name":"GSK","drug_phase":"marketed","molecular_target":"5-HT 1B/1D receptors","drug_class":"Serotonin-1b and Serotonin-1d Receptor Agonist","quality_score":75,"revenue":null,"mechanism":"Naratriptan treats migraines by binding to 5-HT 1B/1D receptors, causing cranial vessel constriction and inhibiting neuropeptide release."},{"drug_id":"rizatriptan-benzoate","indication_name":"Acute treatment of migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"RIZATRIPTAN BENZOATE","company_name":"","drug_phase":"marketed","molecular_target":"5-HT 1B/1D receptors","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Rizatriptan treats migraines by binding to 5-HT 1B/1D receptors on blood vessels and nerves."},{"drug_id":"methysergide","indication_name":"Migraine Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Deseril","generic_name":"METHYSERGIDE","company_name":"","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A","drug_class":"methysergide","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"topiramate","indication_name":"Migraine Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Topamax","generic_name":"topiramate","company_name":"Janssen","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 1 group I member 2, Carbonic anhydrase 1, Carbonic anhydrase 12","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"sodium valproate","indication_name":"Migraine Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Epilim","generic_name":"sodium valproate","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Alcohol dehydrogenase [NADP(+)], Histone deacetylase 1, Histone deacetylase 2","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"rizatriptan","indication_name":"Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Maxalt","generic_name":"RIZATRIPTAN","company_name":"Gensco","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1D","drug_class":"Serotonin-1b and Serotonin-1d Receptor Agonist","quality_score":75,"revenue":null,"mechanism":"Maxalt works by binding to serotonin receptors in the brain to relieve migraine pain."},{"drug_id":"frovatriptan","indication_name":"Migraine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Frova","generic_name":"FROVATRIPTAN","company_name":"Endo Operations","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1D","drug_class":"Serotonin-1b and Serotonin-1d Receptor Agonist","quality_score":62,"revenue":null,"mechanism":"Frova works by binding to serotonin receptors in the brain to relieve migraine symptoms."},{"drug_id":"zavegepant","indication_name":"Migraine with aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zavzpret","generic_name":"zavegepant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Calcitonin gene-related peptide (CGRP) receptor","drug_class":"CGRP receptor antagonist","quality_score":68,"revenue":null,"mechanism":"Zavegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist for acute migraine treatment."},{"drug_id":"zavegepant","indication_name":"Migraine without aura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zavzpret","generic_name":"zavegepant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Calcitonin gene-related peptide (CGRP) receptor","drug_class":"CGRP receptor antagonist","quality_score":68,"revenue":null,"mechanism":"Zavegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist for acute migraine treatment."}],"pipeline":[{"drug_id":"bhv-3500-zavegepant","indication_name":"Acute migraine","indication_type":"pipeline","phase":"Phase 3","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BHV-3500 (zavegepant)","generic_name":"bhv-3500-zavegepant","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"CGRP receptor (calcitonin gene-related peptide receptor)","drug_class":"CGRP receptor antagonist","quality_score":30,"revenue":null,"mechanism":"Zavegepant is a CGRP receptor antagonist that blocks neuropeptide signaling to reduce migraine pain and associated symptoms."},{"drug_id":"rimegepant-75-mg","indication_name":"Acute treatment of migraine with or without aura","indication_type":"pipeline","phase":"Phase 3","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rimegepant 75 MG","generic_name":"rimegepant-75-mg","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"Calcitonin gene-related peptide (CGRP) receptor","drug_class":"CGRP receptor antagonist (gepant)","quality_score":25,"revenue":null,"mechanism":"Rimegepant selectively antagonizes the calcitonin gene-related peptide (CGRP) receptor to block migraine pain signaling."},{"drug_id":"rimegepant-75-mg","indication_name":"Preventive treatment of episodic migraine","indication_type":"pipeline","phase":"Phase 4","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rimegepant 75 MG","generic_name":"rimegepant-75-mg","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"Calcitonin gene-related peptide (CGRP) receptor","drug_class":"CGRP receptor antagonist (gepant)","quality_score":25,"revenue":null,"mechanism":"Rimegepant selectively antagonizes the calcitonin gene-related peptide (CGRP) receptor to block migraine pain signaling."},{"drug_id":"rimegepant-75-mg","indication_name":"Preventive treatment of menstrual migraine","indication_type":"pipeline","phase":"Phase 3","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rimegepant 75 MG","generic_name":"rimegepant-75-mg","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"Calcitonin gene-related peptide (CGRP) receptor","drug_class":"CGRP receptor antagonist (gepant)","quality_score":25,"revenue":null,"mechanism":"Rimegepant selectively antagonizes the calcitonin gene-related peptide (CGRP) receptor to block migraine pain signaling."},{"drug_id":"rimegepant-75-mg","indication_name":"Acute treatment of migraine in pediatric subjects","indication_type":"pipeline","phase":"Phase 3","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rimegepant 75 MG","generic_name":"rimegepant-75-mg","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"Calcitonin gene-related peptide (CGRP) receptor","drug_class":"CGRP receptor antagonist (gepant)","quality_score":25,"revenue":null,"mechanism":"Rimegepant selectively antagonizes the calcitonin gene-related peptide (CGRP) receptor to block migraine pain signaling."}],"offLabel":[],"totalMarketed":165,"totalPipeline":5},"trials":{"data":[{"nct_id":"NCT03847753","title":"Exploring the Comorbidity Between Mental Disorders and General Medical Conditions","phase":"","overall_status":"COMPLETED","enrollment_count":5940299,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT05780580","title":"Prescription of Triptans in the Grand Est Region, France","phase":"","overall_status":"COMPLETED","enrollment_count":4275652,"lead_sponsor_name":"Centre Hospitalier Régional Metz-Thionville","has_results":false},{"nct_id":"NCT05418218","title":"International Headache Registry Study","phase":"","overall_status":"RECRUITING","enrollment_count":200000,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT05854992","title":"Treatments of Migraine with Triptans in Individuals with Elevated Cardiovascular Risk and in Pregnant Women","phase":"","overall_status":"COMPLETED","enrollment_count":68419,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT06976723","title":"Nerivio Efficacy by Time of Treatment Onset","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":55261,"lead_sponsor_name":"Theranica","has_results":false},{"nct_id":"NCT07227194","title":"Machine Learning Assessment of Next-Day Migraine Likelihood","phase":"","overall_status":"COMPLETED","enrollment_count":53065,"lead_sponsor_name":"Theranica","has_results":false},{"nct_id":"NCT06023953","title":"Migraine With and Without Aura Characteristics and Response to Remote Electrical Neuromodulation (REN) Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":31715,"lead_sponsor_name":"Theranica","has_results":false},{"nct_id":"NCT04992897","title":"Real-world Data Analysis of REN Treatment in Migraine Patients","phase":"","overall_status":"COMPLETED","enrollment_count":12151,"lead_sponsor_name":"Theranica","has_results":false},{"nct_id":"NCT04806620","title":"Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Brain Inflammation Collaborative","has_results":false},{"nct_id":"NCT04939922","title":"China Headache and Vertigo Registry Study","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT05334927","title":"China HeadAche DIsorders RegiStry","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Beijing Tiantan Hospital","has_results":false},{"nct_id":"NCT01125774","title":"Telcagepant for Prevention of Menstrually Related Migraine in Female Participants With Episodic Migraine (MK-0974-065)","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":4548,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT03266588","title":"Open Label Safety Study in Acute Treatment of Migraine","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":3019,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT07497854","title":"A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT06583395","title":"Quest to Analyze One Thousand Humans Meditating","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":3000,"lead_sponsor_name":"Tobias Moeller-Bertram","has_results":false},{"nct_id":"NCT06439628","title":"ARISE-A Chinese Real-world Study of Rimegepant for the Acute Treatment of Migraine","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false},{"nct_id":"NCT06150781","title":"Aimovig Pregnancy Exposure Registry","phase":"","overall_status":"RECRUITING","enrollment_count":2842,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT05087420","title":"Migraine in Poland - a Web-based Cross-sectional Survey","phase":"","overall_status":"COMPLETED","enrollment_count":2800,"lead_sponsor_name":"Swiat Zdrowia","has_results":false},{"nct_id":"NCT07103694","title":"i-NEED: NEw migrainE Drugs Database","phase":"","overall_status":"RECRUITING","enrollment_count":2641,"lead_sponsor_name":"IRCCS San Raffaele Roma","has_results":false},{"nct_id":"NCT06353100","title":"Chronic Pain in the General Population of Chile","phase":"","overall_status":"COMPLETED","enrollment_count":2365,"lead_sponsor_name":"Pontificia Universidad Catolica de Chile","has_results":false},{"nct_id":"NCT02565186","title":"An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2171,"lead_sponsor_name":"Eli Lilly and Company","has_results":true},{"nct_id":"NCT03872453","title":"Acute Treatment Trial in Adult Subjects With Migraines","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":2154,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT04649242","title":"Randomized Study in Children and Adolescents With Migraine: Acute Treatment","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":2100,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT04384367","title":"Efficacy and Safety of Rizatriptan-Naproxen (10/550 Mg) in the Acute Treatment of Migraine","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2068,"lead_sponsor_name":"Eurofarma Laboratorios S.A.","has_results":false},{"nct_id":"NCT07163416","title":"(Italian Migraine Registry, I-GRAINE-NEW)","phase":"","overall_status":"RECRUITING","enrollment_count":2030,"lead_sponsor_name":"IRCCS San Raffaele Roma","has_results":false},{"nct_id":"NCT04623203","title":"The Prognosis of Migraine and Tension-Type Headache in Children and Adolescents","phase":"","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"Bnai Zion Medical Center","has_results":false},{"nct_id":"NCT07336056","title":"Nerivio Efficacy Under High-Frequency Use","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Theranica","has_results":false},{"nct_id":"NCT04571060","title":"Randomized Trial in Adult Participants With Acute Migraines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1978,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT00071786","title":"Family Study of Affective and Anxiety Spectrum Disorders","phase":"","overall_status":"COMPLETED","enrollment_count":1944,"lead_sponsor_name":"National Institute of Mental Health (NIMH)","has_results":false},{"nct_id":"NCT00483704","title":"Multiple Attacks Study to Compare the Efficacy and Safety of MK-0974 With Placebo for Acute Migraine (MK-0974-031)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1935,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT02638103","title":"Efficacy and Safety of Subcutaneous Administration of Fremanezumab (TEV-48125) for the Preventive Treatment of Migraine","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1890,"lead_sponsor_name":"Teva Branded Pharmaceutical Products R&D, Inc.","has_results":true},{"nct_id":"NCT05177406","title":"Healthcare Costs and Resource Utilization in Aimovig Migraine Patients: a Retrospective Study Using United States Claims Data","phase":"","overall_status":"COMPLETED","enrollment_count":1839,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03461757","title":"Trial in Adult Subjects With Acute Migraines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1811,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT04804033","title":"A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention","phase":"PHASE2, PHASE3","overall_status":"TERMINATED","enrollment_count":1753,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT02867709","title":"Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1686,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT02828020","title":"Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1672,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT04574362","title":"Safety and Efficacy Trial of BHV3000 (Rimegepant) 75 mg for the Acute Treatment of Migraine","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1648,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03670810","title":"A Study of Lasmiditan (LY573144) Over Four Migraine Attacks","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1633,"lead_sponsor_name":"Eli Lilly and Company","has_results":true},{"nct_id":"NCT05443659","title":"Real-world Data Analysis of REN Treatment in Adolescence With Migraine","phase":"","overall_status":"COMPLETED","enrollment_count":1629,"lead_sponsor_name":"Theranica","has_results":true},{"nct_id":"NCT03896009","title":"Maximizing Outcomes in Treating Acute Migraine","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1594,"lead_sponsor_name":"Axsome Therapeutics, Inc.","has_results":true},{"nct_id":"NCT04940390","title":"A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1591,"lead_sponsor_name":"Satsuma Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT03732638","title":"Efficacy and Safety Trial of Rimegepant for Migraine Prevention in Adults","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":1590,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT06532357","title":"A Study to Learn About the Benefit of Rimegepant Versus Triptans in Migraine Buddy App Users.","phase":"","overall_status":"COMPLETED","enrollment_count":1536,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT06267664","title":"Real-world Effectiveness and Tolerability of Triptans-Ditans-Gepants (TRIDIGEP)","phase":"","overall_status":"UNKNOWN","enrollment_count":1500,"lead_sponsor_name":"Hospital Clínico Universitario de Valladolid","has_results":false},{"nct_id":"NCT05281770","title":"Monoclonal CGRP Antibodies for Migraine Prevention - a Nationwide Real Life Study","phase":"","overall_status":"UNKNOWN","enrollment_count":1500,"lead_sponsor_name":"Austrian Migraine Registry Collaboration","has_results":false},{"nct_id":"NCT03418766","title":"The Relationship Between Right-to-left Shunt and Brain White Matter Lesions in Patients With Migraine","phase":"","overall_status":"UNKNOWN","enrollment_count":1500,"lead_sponsor_name":"The First Hospital of Jilin University","has_results":false},{"nct_id":"NCT03237845","title":"Safety and Efficacy in Adult Subjects With Acute Migraines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1499,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03235479","title":"Safety and Efficacy Study in Adult Subjects With Acute Migraines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1485,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT05217927","title":"Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":1415,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT05989048","title":"A Study to Learn About Zavegepant as the Acute Treatment of Migraine in Asian Adults","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1414,"lead_sponsor_name":"Pfizer","has_results":false}],"total":50},"guidelines":[{"drug_id":"paracetamol","guideline_body":"FDA label","recommendation":"temporarily relieves migraine","line_of_therapy":"1L","evidence_grade":"B","guideline_year":null}],"source":"Drug Landscape verified database"}